Skip to content

An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery

An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05458453
Enrollment
80
Registered
2022-07-14
Start date
2022-07-07
Completion date
2023-02-28
Last updated
2023-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esketamine, Thoracoscopic Surgery

Brief summary

Thoracic surgery can produce severe postoperative acute pain, which can easily lead to cough weakness, atelectasis, respiratory restriction, pneumonia, hypoxemia, secretion retention, respiratory failure and other adverse events. Esketamine can reduce the demand of analgesic opioids, reduce the respiratory depression caused by opioids, improve ventilation, significantly reduce postoperative pain and prolong the analgesic time after thoracic surgery. Therefore, the application of esketamine in postoperative analgesia of patients undergoing thoracoscopic surgery may help to improve the respiratory function of clinical patients and further improve the postoperative analgesia effect, so as to achieve the purpose of accelerating the surgical rehabilitation of patients undergoing thoracoscopic surgery. Esketamine is rarely used in perioperative period in China, and the development of its safe and reasonable application methods and potential role in perioperative anesthesia needs further research and verification. Generally speaking, at present, there is still a lack of evaluation of ketamine in improving respiratory function, pain, anxiety and depression after thoracoscopic surgery, and there is no direct clinical evidence. At present, sufentanil is the most commonly used drug for postoperative analgesia in patients undergoing clinical surgery. As a strong opioid, although sufentanil can provide good analgesic effect, the respiratory depression caused by sufentanil is not conducive to the recovery of postoperative lung function in patients undergoing thoracic surgery. The action sites of esketamine include N- methyl-aspartic acid (NMDA) receptor, opioid receptor, monoamine receptor, M cholinergic receptor, sodium channel, calcium channel, etc., which can relieve respiratory depression caused by opioids, stimulate respiration, relax airway smooth muscle, prevent hyperalgesia caused by opioids, reduce the dosage of postoperative analgesics and prolong the duration of postoperative analgesia. Therefore, esketamine is likely to improve postoperative respiratory function of patients after thoracoscopic surgery and play a good role. To sum up, this study is intended to include patients undergoing elective thoracoscopic surgery. Through a prospective randomized controlled double-blind clinical trial, different analgesic drugs of intravenous patient-controlled analgesia and simple conventional opioid analgesic sufentanil are used as the control. Combined with the investigation of preoperative and postoperative tidal volume, oxygenation index, postoperative pain and postoperative recovery outcome, the effects of esketamine on postoperative respiratory function, postoperative pain and overall rehabilitation of these patients are compared, so as to provide direct clinical evidence for improving postoperative lung function of patients undergoing elective thoracoscopic surgery, and at the same time, provide a choice for thoracoscopic surgery. To explore the effect of esketamine on improving postoperative respiratory function, pain, depression and anxiety and overall rehabilitation of patients undergoing thoracoscopic surgery. Compound esketamine is used for postoperative analgesia, thus providing direct clinical evidence for improving postoperative pulmonary function of patients undergoing elective thoracoscopic surgery, and providing reference for improving postoperative pain, anxiety and depression of patients undergoing elective thoracoscopic surgery.

Interventions

DRUGEsketamine

Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing thoracoscopic surgery are required to use PCIA for analgesia; 2. ASA grade I-III; 3. The patient's age is 18-75 years old; 4、18.5 \< BMI \< 28; 5\. Obtain the informed consent of patients and their families;

Exclusion criteria

1. Patients with previous history of thoracic surgery or combined history of thoracic trauma; 2. Patients with severe hypertension and poor control; 3. Patients with hyperthyroidism and poor control; 4. Patients at risk of increased intracranial pressure; 5. Patients with mental illness; 6. Patients who are allergic to any drug in the test; 7. Patients who take anti-inflammatory drugs, opioids or related diseases for a long time; 8. Pregnant or lactating patients;

Design outcomes

Primary

MeasureTime frameDescription
Respiratory rate 5day 2 ( second afternoon after surgery)Respiratory rate on the next afternoon after surgery
Minute ventilation volume 0Before anesthesia inductionMinute ventilation volume before anesthesia induction
Minute ventilation volume 1Within 5 minutes after extubationMinute ventilation volume after extubation
Minute ventilation volume 2postoperative day 1 (POD1) morningMinute ventilation volume on the first morning
Minute ventilation volume 3postoperative day 1 (POD1) afternoonMinute ventilation volume on the first afternoon
Minute ventilation volume 4postoperative day 2 (POD2) morningMinute ventilation volume on the next morning
Minute ventilation volume 5postoperative day 2 (POD2) afternoonMinute ventilation volume on the next afternoon
Tidal volume 0Before anesthesia inductionTidal volume before anesthesia induction
Tidal volume 1Within 5 minutes after extubationTidal volume after extubation
Tidal volume 2Day1 (The first morning after surgery)Tidal volume on the first morning after surgery
Tidal volume 3Day1(The afternoon of the first day after surgery)Tidal volume on the first afternoon after surgery
Tidal volume 4day 2 ( second morning after surgery)Tidal volume on the next morning after surgery
Tidal volume 5day 2 ( second afternoon after surgery)Tidal volume on the next afternoon after surgery
Respiratory rate 0Before anesthesia inductionRespiratory rate before anesthesia induction
Respiratory rate 1Within 5 minutes after extubationRespiratory rate after extubation
Respiratory rate 2Day1 (The first morning after surgery)Respiratory rate on the first morning after surgery
Respiratory rate 3Day1 (The afternoon of the first day after surgery)Respiratory rate on the first afternoon after surgery
Respiratory rate 4day 2 ( second morning after using surgery)Respiratory rate on the next morning after surgery

Secondary

MeasureTime frameDescription
Vas score 5postoperative day 2 (POD2) afternoonThe higher the score, the more painful it is.
Oxygenation index 0Before anesthesia inductionOxygenation index (calculated as PaO2/FiO2) before anesthesia induction
Oxygenation index 1Within 5 minutes after extubationOxygenation index (calculated as PaO2/FiO2) after extubation
Oxygenation index 3postoperative Day 1Oxygenation index (calculated as PaO2/FiO2) on the first morning
Incidence of postoperative pulmonary complications during hospitalizationFrom end of the surgery to hospital discharge with about mean of 7 days after surgerypostoperative pulmonary complications during hospitalization was assessed using the Melbourne Group Scale, whcih reached four or more of the 8 criteria would be diagnosed with postoperative pulmonary complications.
incidence of hypoxemia during the first and second day after surgeryfrom end of the surgery to the second day after surgeryhypoxemia is defined as SpO2\<92% during the first and second day after surgery
Vas score 1Within 5 minutes after extubationThe higher the score, the more painful it is.
Vas score 2postoperative day 1 (POD1) morningThe higher the score, the more painful it is.
Vas score 3postoperative day 1 (POD1) afternoonThe higher the score, the more painful it is.
Vas score 4postoperative day 2 (POD2) morningThe higher the score, the more painful it is.

Other

MeasureTime frameDescription
Depression scale 0Before anesthesia inductionPHQ-9, The higher the score, the more depressed.
Depression scale 4day 2 ( second morning after using PCIA)PHQ-9,The higher the score, the more depressed.
anxiety score 0Before anesthesia inductionGAD-7,The higher the score, the more anxious.
anxiety score 2Day1(the first morning after using PCIA)GAD-7,The higher the score, the more anxious.
anxiety score 4day 2 ( second morning after using PCIA)GAD-7,The higher the score, the more anxious.
sleep quality during the first two days after surgeryfrom end of the surgery to the second day after surgeryassessed by Richards-Campbell sleep score, which higher socre represents better sleep quality
Depression scale 2Day 1(the first morning after using PCIA)PHQ-9,The higher the score, the more depressed.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026